You just read:

Glenmark Pharmaceuticals Reports Positive Data in a Phase 2a Study of GBR 830 for the Treatment of Patients with Atopic Dermatitis

News provided by

Glenmark Pharmaceuticals

Jul 31, 2017, 11:41 ET